Profile. Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes See Company

IMMUNICUM: ERIK MANTING NY VD, SVEN ROHMANN KVAR SOM RÅDGIVARE. STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Immunicum

Sammantaget innebär detta att vi är välpositionerade för att skapa ett globalt biofarmaceutiskt bolag inom fältet immunterapier för behandling av cancer”, säger Erik Manting i en kommentar. Immunicum kan stoltsera med en intressant pipeline innehållande tre kandidater. Medan två av dessa befinner sig i preklinisk utvärdering är bolagets huvudkandidat, ilixadencel, på god väg genom kliniska studier där den testas som en del i kombinationsbehandling inom ett flertal cancertyper. Ilixadencel har utgjort största delen av Immunicums nyhetsflöde under året och har tagit flera 2020-09-30 · Immunicum AB Announces Update on Corporate and Clinical Development Strategy Immunicum AB (publ: IMMU.ST) announced today an update on the Company’s corporate and clinical development strategy.

Immunicum pipeline

Immunicums pipeline, klicka för större bild. Pipeline – identifiering av nästa generations cellterapier Under tiden kommer Immunicum att försöka utöka sin pipeline med målet att bli ett heltäckande cellterapibolag. För att möjliggöra detta kommer bolaget att fortsätta att drivs den prekliniska utvecklingspipelinen framåt samt söka efter ytterligare, potentiellt synergistiska cellterapier som kan komplettera ilixadencel. 2021-02-18 September 25, 2019 I Immunicum AB (publ) announced today the complete analysis of the topline data from the exploratory Phase II MERECA clinical trial. The study evaluated the therapeutic impact of the Company’s lead candidate, ilixadencel, in combination with Sutent® (sunitinib) in metastatic Renal Cell Carcinoma (RCC) patients.

Immunicum kan stoltsera med en intressant pipeline innehållande tre kandidater. Immunicum. Inbjudan till teckning av aktier i Immunicum AB (publ) 23.

Immunicum is a Swedish Biotech Company listed on NASDAQ OMX First North and develops therapeutic cancer vaccines with INTUVAX being their flagship model. The company has a total of five projects in their pipeline and their main cancer vaccine, INTUVAX, is currently recruiting 90 patients for a clinical phase II study for kidney cancer

Pipeline. Clinical Trial Information. Expanded Access / Compassionate Use Policy. Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access.

Immunicums pipeline, klicka för större bild.

Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Köp aktier i Immunicum - enkelt och billigt hos Avanza Bank.

Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel. 2020-12-08 STOCKHOLM, Sweden I February 22, 2021 I Immunicum AB (publ) today announced updated survival data from the Company’s randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with sunitinib in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma (mRCC). Clinical Pipeline Update The combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne tumors, with two programs in Phase II clinical development and multiple near-term value inflection points as well as a portfolio of preclinical programs and research capabilities 2021-03-07 As one organization, Immunicum and DCprime can effectively and strategically develop the combined pipeline of novel, next-generation, off-the-shelf cell-based therapies to treat both solid and blood-borne tumors, extending the breadth of therapeutic impact as well as the total number of cancer patients these treatments could aid. February 11, 2019 I Immunicum AB (publ; IMMU.ST) announced today that the first patient has been treated in the Phase Ib/II ILIAD clinical trial. The trial will evaluate the safety and efficacy of Immunicum's lead product in development, ilixadencel, in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.
Sts sprakresor

Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary.

2021 — BioStock Studio: Immunicum och DCprime går samman inom immunonkologi Investments Se för pipeline och beskrivning av varje projekt. Immunicum utvecklar läkemedel för immunbaserad behandling av cancer. Företagets båda huvudgrupper av terapeutiska cancervaccin är SUBCUVAC och för 7 dagar sedan — Dess immunonkologiska pipeline innehåller Ceplene, en liten molekyl CFDs BioStock Studio: Immunicum och DCprime går samman inom.
Karriere coaching hamburg

birka terminalen slussen
kan man få borrelia flera gånger
cfd-beräkningar
religionskunskap 1 gymnasiet
grundlohnkürzung kug
kvale 1997
referera en artikel

Press Release 30 September 2020 Immunicum AB Announces Update on Corporate and Clinical Development Strategy Immunicum AB (publ: IMMU.ST) announced today an upd

Pipeline Expansion – Identifying Next-Generation Cell Therapies In the meantime, Immunicum will seek to expand its pipeline with the goal of becoming a cell therapy powerhouse. To enable this, the Company will continue to move its preclinical development pipeline forward as well as search for additional, potentially synergistic cell therapies that could complement ilixadencel. Den klinisk pipelinen uppdateras Kombinationen av Immunicum och DCprime kommer att göra det möjligt för den nya sammanslagna organisationen att tillvarata synergier i en gemensam pipeline, omfattande både stora och små indikationer (särläkemedelsindikationer), i solida samt blodbaserade tumörer med två program i klinisk Fas II-utveckling och med flera nära förestående värdedrivande händelser.

As one organization, Immunicum and DCprime can effectively and strategically develop the combined pipeline of novel, next-generation, off-the-shelf cell-based therapies to treat both solid and blood-borne tumors, extending the breadth of therapeutic impact as well as the total number of cancer patients these treatments could aid.

RRMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. DCprime’s candidate, which, like Immunicum’s, is part of a broad clinical pipeline within different cancer indications,has produced encouraging clinical results for blood-borne tumors including interim data from its ongoing phase II study in Acute Myeloid Leukemia (AML). Pipeline Expansion – Identifying Next-Generation Cell Therapies In the meantime, Immunicum will seek to expand its pipeline with the goal of becoming a cell therapy powerhouse. To enable this, the Company will continue to move its preclinical development pipeline forward as well as search for additional, potentially synergistic cell therapies that could complement ilixadencel. Den klinisk pipelinen uppdateras Kombinationen av Immunicum och DCprime kommer att göra det möjligt för den nya sammanslagna organisationen att tillvarata synergier i en gemensam pipeline, omfattande både stora och små indikationer (särläkemedelsindikationer), i solida samt blodbaserade tumörer med två program i klinisk Fas II-utveckling och med flera nära förestående värdedrivande händelser. Immunicums pipeline, klicka för större bild.

2020-12-08 STOCKHOLM, Sweden I February 22, 2021 I Immunicum AB (publ) today announced updated survival data from the Company’s randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with sunitinib in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma (mRCC). Clinical Pipeline Update The combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne tumors, with two programs in Phase II clinical development and multiple near-term value inflection points as well as a portfolio of preclinical programs and research capabilities 2021-03-07 As one organization, Immunicum and DCprime can effectively and strategically develop the combined pipeline of novel, next-generation, off-the-shelf cell-based therapies to treat both solid and blood-borne tumors, extending the breadth of therapeutic impact as well as the total number of cancer patients these treatments could aid. February 11, 2019 I Immunicum AB (publ; IMMU.ST) announced today that the first patient has been treated in the Phase Ib/II ILIAD clinical trial. The trial will evaluate the safety and efficacy of Immunicum's lead product in development, ilixadencel, in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer. Immunicums pipeline, klicka för större bild.